(Q39693833)

14 September 2017

title

Preneoplastic changes persist after IGF-IR downregulation and tumor regression (English)

1 reference

14 September 2017

R A Jones

1

1 reference

14 September 2017

J J Petrik

series ordinal

2

1 reference

14 September 2017

R A Moorehead

series ordinal

3

1 reference

14 September 2017

language of work or name

English

0 references

publication date

14 June 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

29

1 reference

14 September 2017

issue

34

1 reference

14 September 2017

page(s)

4779-4786

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2010.231

14 September 2017

exact match

0 references

cites work

Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II)

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

The insulin-like growth factor system and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Type I insulin-like growth factor receptor induces pulmonary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

The IGF‐1 receptor in cancer biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Sustained loss of a neoplastic phenotype by brief inactivation of MYC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Reversibility and recurrence of IGF-IR-induced mammary tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Gefitinib potentiates myeloid cell differentiation by ATRA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Residual disease after neoadjuvant chemotherapy for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Herceptin: mechanisms of action and resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

The IGF system and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Function of the IGF-I receptor in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Delayed onset of Igf2-induced mammary tumors in Igf2r transgenic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.231

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.231

1 reference

Dimensions Publication ID

14 September 2017

1053628658

0 references

1 reference